Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Droloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 13/20 | 0.82 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | TP53 | P04637 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | ESRRG | P62508 | 3/20 | 0.82 |
| ▸ | PGR | P06401 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.82 |
| ▸ | ESRRB | O95718 | 2/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | PLD2 | O14939 | 1/20 | 0.82 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Droloxifene SCHEMBL30728607 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL1151787 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL30534774 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL5030004 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL4843 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL4842 | 1.00 | ESR1 (0.82) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL750110 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL9782633 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL28095331 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 | |
| Droloxifene SCHEMBL28095329 | 0.99 | ESR1 (0.80) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110325533-A | INHIBITORS OF THE MENIN-MLL INTERACTION | 生命医药有限责任公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-109789225-A | DNA MONOCLONAL ANTIBODIES TARGETING CHECKPOINT MOLECULES | 宾夕法尼亚大学理事会 | 2019-05-21 | — | — | CN | disclosed |
| CN-104955459-B | Substituted indoles -5- amphyl and its treatment use | 南特知识产权控股有限责任公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-108712904-A | The solid form of two Fluorakil 100s of 2- (4- chlorphenyls)-N- ((2- (2,6- dioxopiperidine -3- bases) -1- oxoisoindolines -5- bases) methyl) -2,2- and its pharmaceutical composition and purposes | 细胞基因公司 | 2018-10-26 | — | — | CN | disclosed |
| CN-108601735-A | Pharmaceutical formulation for cancer treatment | 加利福尼亚大学董事会 | 2018-09-28 | — | — | CN | disclosed |
| CN-108430473-A | Antiproliferative compounds and pharmaceutical compositions and uses thereof | 细胞基因公司 | 2018-08-21 | — | — | CN | disclosed |
| CN-105101959-B | Cyclic sulfonamide-containing derivatives as hedgehog signaling pathway inhibitors | 南特知识产权控股有限责任公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107530347-A | The co-crystal thereof of bruton's tyrosine kinase inhibitor | 药品循环有限责任公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107530346-A | The solvation form of bruton's tyrosine kinase inhibitor | 药品循环有限责任公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107106565-A | BTK inhibitor combinations and dosing regimens | 药品循环有限责任公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-107073115-A | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | 细胞基因公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-104011079-B | HER3 antibody and application thereof | UAB研究基金会 | 2017-06-16 | — | — | CN | disclosed |